<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191135</url>
  </required_header>
  <id_info>
    <org_study_id>7339-009</org_study_id>
    <secondary_id>2019-001892-35</secondary_id>
    <secondary_id>MK-7339-009</secondary_id>
    <secondary_id>KEYLYNK-009</secondary_id>
    <secondary_id>195082</secondary_id>
    <nct_id>NCT04191135</nct_id>
  </id_info>
  <brief_title>Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)</brief_title>
  <official_title>An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of olaparib (MK-7339) plus pembrolizumab
      (MK-3475) with chemotherapy plus pembrolizumab after induction with first-line chemotherapy
      plus pembrolizumab in triple negative breast cancer (TNBC). The primary hypotheses are:

        1. Olaparib plus pembrolizumab prolongs progression-free survival (PFS) compared with
           chemotherapy plus pembrolizumab.

        2. Olaparib plus pembrolizumab is non-inferior to chemotherapy plus pembrolizumab in terms
           of overall survival (OS).

        3. Olaparib plus pembrolizumab prolongs OS compared with chemotherapy plus pembrolizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">January 26, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Participants with Breast Cancer Susceptibility Gene Mutation (BRCAm) Tumors</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants with Breast Cancer Susceptibility Gene Mutation (BRCAm) Tumors</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score</measure>
    <time_frame>Baseline and up to approximately 72 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 scores will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physical Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1- 5 Score</measure>
    <time_frame>Baseline and up to approximately 72 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in physical functioning (EORTC QLQ-C30 Items 1-5) score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Emotional Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 21-24 Score</measure>
    <time_frame>Baseline and up to approximately 72 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 4 questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in emotional functioning (EORTC QLQ-C30 Items 21-24) score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systemic Therapy Side Effects Using the European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality-of-Life (QoL) Questionnaire (EORTC QLQ-BR23) Items 1-4, 6, 7, and 8 Score</measure>
    <time_frame>Baseline and up to approximately 72 months</time_frame>
    <description>EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective) and four symptom scales (systemic therapy side effects, upset by hair loss, arm symptoms, breast symptoms). Participant responses to 7 questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in systemic therapy side effects (EORTC QLQ-BR23 Items 1-4, 6, 7, and 8) score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Health-Related Quality-of-Life (HRQoL) Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 29 and 30 Score</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions &quot;How would you rate your overall health during the past week?&quot; and &quot;How would you rate your overall quality of life during the past week?&quot; are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. TTD was defined as the time from baseline (at randomization) to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in Items 29 and 30 scale scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Physical Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 1- 5 Score</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. TTD was defined as the time from baseline (at randomization) to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in physical functioning Items 1 to 5 scale scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Emotional Functioning Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Items 21-24 Score</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 4 questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. TTD was defined as the time from baseline (at randomization) to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in emotional functioning Items 21-24 scale scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Systemic Therapy Side Effects Using the European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality-of-Life (QoL) Questionnaire (EORTC QLQ-BR23) Items 1-4, 6, 7, and 8 Score</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective) and four symptom scales (systemic therapy side effects, upset by hair loss, arm symptoms, breast symptoms). Participant responses to 7 questions about their systemic therapy side effects are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. TTD was defined as the time from baseline (at randomization) to the first onset of a ≥10-point decrease with confirmation by the subsequent visit of a ≥10-point decrease in systemic therapy side effects Items 1-4, 6, 7 and 8 scale scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Outcomes using the European Quality of Life 5-dimension, 5-level Questionnaire (EuroQoL EQ-5D-5L) Visual Analogue Scale (VAS) Score</measure>
    <time_frame>Baseline and up to approximately 72 months</time_frame>
    <description>The EuroQoL EQ-5D-5L measured health-related outcomes, assessing 5 health state dimensions (mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression) on a 5-point scale from 1 (no problem) to 5 (unable to/extreme problems). The EuroQoL EQ-5D-5L also includes a graded (0 to 100) vertical visual analog scale on which the participant rates their general state of health. The change from baseline in EuroQoL EQ-5D-5L score will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced At Least One Adverse Event (AE)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 72 months</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">932</enrollment>
  <condition>Triple Negative Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>pembrolizumab + carboplatin and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive both carboplatin Area Under The Curve (AUC) 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will continue to receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle in addition to pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle in the post-induction period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab + olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive both carboplatin AUC 2 with gemcitabine 1000 mg/m^2 intravenously on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle during the induction period for 4-6 cycles. After the induction period, participants will receive pembrolizumab 200 mg intravenously on Day 1 of each 21-day cycle plus olaparib 300 mg orally twice daily during the post-induction period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>intravenous (IV) infusion</description>
    <arm_group_label>pembrolizumab + carboplatin and gemcitabine</arm_group_label>
    <arm_group_label>pembrolizumab + olaparib</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>pembrolizumab + olaparib</arm_group_label>
    <other_name>LYNPARZA®</other_name>
    <other_name>MK-7339</other_name>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>pembrolizumab + carboplatin and gemcitabine</arm_group_label>
    <arm_group_label>pembrolizumab + olaparib</arm_group_label>
    <other_name>PARAPLATIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>pembrolizumab + carboplatin and gemcitabine</arm_group_label>
    <arm_group_label>pembrolizumab + olaparib</arm_group_label>
    <other_name>GEMZAR®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Induction Period:

          -  Has locally recurrent inoperable TNBC that has not previously been treated with
             chemotherapy and that cannot be treated with curative intent OR has metastatic TNBC
             that has not been previously treated with chemotherapy

          -  Has been treated with anthracycline and/or a taxane in the neoadjuvant/adjuvant
             setting, if they received systemic treatment in the neoadjuvant/adjuvant setting,
             unless anthracycline and/or taxane was contraindicated or not considered the best
             treatment option for the participant in the opinion of the treating physician

          -  Has measurable disease based on RECIST 1.1

          -  Has provided a recently obtained or archival (no more than 3 years old) core or
             excisional biopsy of a tumor lesion not previously irradiated

          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 as
             assessed within 7 days prior to the start of induction study treatment

          -  Has a life expectancy ≥27 weeks from the day of first study treatment

          -  A male participant must agree to be abstinent or use contraception and refrain from
             donating sperm during the intervention period and for at least 180 days after the last
             dose of study treatment

          -  A female participant must not be pregnant or breastfeeding and must agree to the
             following if is a woman of childbearing potential (WOCBP): have a negative pregnancy
             test within 24 hours before the start of study treatment and agree to be abstinent or
             use contraception and refrain from donating eggs (ova, oocytes) during the
             intervention period and for at least 180 days after the last dose of study treatment

        Post-induction Period:

          -  Has received up to 6 cycles but not less than 4 cycles of induction therapy without
             permanently discontinuing from pembrolizumab or both carboplatin and gemcitabine

          -  Has achieved complete response (CR), partial response (PR), or stable disease (SD)
             based on RECIST 1.1 by Blinded Independent Central Review (BICR) at the Week 18
             evaluation

          -  Is able to complete during post-induction at least the Cycle 1, Day 1 doses of
             olaparib and pembrolizumab or the Cycle 1, Day 1 doses of at least one of the
             chemotherapy agents being administered at the end of induction (carboplatin and/or
             gemcitabine) in addition to pembrolizumab

          -  Has ECOG performance status of 0 or 1, as assessed within 7 days prior to the start of
             post-induction study treatment

          -  Has no higher than Grade 1 toxicities related to induction therapy (excluding
             alopecia) prior to randomization

        Exclusion Criteria:

        Induction Period:

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 5 years with the exception of basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, or carcinoma in situ (eg, cervical cancer in
             situ) that have undergone potentially curative therapy

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior the first dose of study treatment

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis

          -  Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features
             suggestive of MDS/AML

          -  Has a history of (non-infectious) pneumonitis that required steroids or current
             pneumonitis

          -  Has active, or a history of, interstitial lung disease

          -  Has a known history of active tuberculosis

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
             reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is
             detected) infection

          -  Has a history of class II-IV congestive heart failure or myocardial infarction within
             6 months of first study treatment

          -  Has neuropathy ≥Grade 2

          -  Has not recovered (eg, to ≤Grade 1 or to baseline) from AEs due to a previously
             administered therapy

          -  Has a known history of hypersensitivity or allergy to pembrolizumab, olaparib and any
             of its components, and/or to any of the study chemotherapies (eg, carboplatin or
             gemcitabine) and any of their components

          -  Has severe hypersensitivity (≥Grade 3) to the study treatments and/or any of their
             excipients

          -  Has a known psychiatric or substance abuse disorder that would interfere with the
             participant's ability to cooperate with the requirements of the study

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study, starting with the Screening Visit through 180 days
             after the last dose of study treatment

          -  Is a WOCBP who has a positive urine pregnancy test within 24 hours prior to
             randomization or treatment allocation

          -  Has received prior therapy with either olaparib or any other poly adenosine
             diphosphate ribose polymerase (PARP) inhibitor

          -  Has received prior radiotherapy within 2 weeks of start of study treatment

          -  Has received colony-stimulating factors (eg, granulocyte colony stimulating factor
             [G-CSF], granulocyte macrophage colony stimulating factor [GM-CSF] or recombinant
             erythropoietin) within 2 weeks prior to the first dose of study treatment

          -  Has had an allogenic tissue/solid organ transplant.

          -  Has received previous allogenic bone marrow transplant or double umbilical cord
             transplantation (dUCBT)

          -  Has had major surgery within 2 weeks of starting study treatment or has not recovered
             from any effects of any major surgery

          -  Has received a live vaccine within 30 days prior to first study treatment

          -  Is receiving any medication prohibited in combination with study chemotherapies unless
             medication was stopped within 7 days prior to first study treatment

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with
             an agent directed to another co-inhibitory T cell receptor (such as cytotoxic
             T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137) or has previously
             participated in a study evaluating pembrolizumab regardless of treatment received

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment

          -  Has a resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible
             cardiac conditions, as judged by the investigator

          -  Has a history or current evidence of any condition (eg, cytopenia,
             transfusion-dependent anemia, or thrombocytopenia), therapy, or laboratory abnormality
             that might confound the results of the study, interfere with the participant's
             involvement for the full duration of the study, or is not in the best interest of the
             participant to be involved, in the opinion of the treating investigator

          -  Is either unable to swallow orally administered medication or has a gastrointestinal
             disorder affecting absorption (eg, gastrectomy, partial bowel obstruction,
             malabsorption)

          -  Is unlikely to comply with the study procedures, restrictions, and requirements of the
             study; as judged by the investigator

        Post-induction Period:

          -  Has severe hypersensitivity (≥Grade 3) to the study treatments and/or any of their
             excipients

          -  Has permanently discontinued from both carboplatin and gemcitabine during induction
             due to toxicity

          -  Has permanently discontinued from pembrolizumab during induction due to toxicity

          -  Has received less than 4 cycles of chemotherapy plus pembrolizumab during induction

          -  Is currently receiving either strong or moderate inhibitors of cytochrome P450
             (CYP)3A4 that cannot be discontinued for the duration of the study

          -  Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be
             discontinued for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Cancer Care ( Site 0142)</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>831-375-4105</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute ( Site 0111)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-582-7455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare ( Site 0104)</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>707-521-3814</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester CC ( Site 0146)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-270-3435</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University ( Site 0129)</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-721-4430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System ( Site 0103)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-9826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute ( Site 0157)</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>612-863-1093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center For Cancer And Blood Disorders ( Site 0151)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>817-759-7013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical ( Site 0117)</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-703-2398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 0128)</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-574-3494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0005)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>41694645012245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre ( Site 0002)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514934193435800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sociedad de Investigaciones Medicas Limitadas ( Site 0510)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56974316500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IC La Serena Research ( Site 0511)</name>
      <address>
        <city>La Serena</city>
        <state>Coquimbo</state>
        <zip>1720430</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56993718661</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez ( Site 0500)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56990101775</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile ( Site 0501)</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana De Santiago</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56223546919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncocentro ( Site 0502)</name>
      <address>
        <city>Viña del Mar</city>
        <state>Valparaiso</state>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56323320859</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0601)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050030</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573002608134</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0600)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573017861657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Organizacion Clinica Bonnadona-Prevenir S.A.S. ( Site 0609)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573226524208</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica S.A. ( Site 0606)</name>
      <address>
        <city>Monteria</city>
        <state>Cordoba</state>
        <zip>230002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573157962122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0602)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5723319090</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hemato Oncologos S.A. ( Site 0603)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573003459244</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard ( Site 1018)</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478782644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU-Jean Minjoz ( Site 1013)</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33370632256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud IUCT Oncopole ( Site 1001)</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+0033531155870</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Cancerologie du Grand Montpellier ( Site 1009)</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33467926155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin ( Site 1003)</name>
      <address>
        <city>Clermont-Ferrand Cedex 01</city>
        <state>Puy-de-Dome</state>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33473278137</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel ( Site 1020)</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33232082575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hopital Sud ( Site 1023)</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33322455499</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy ( Site 1010)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33142116159</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynaekologisch-onkologische Praxis Hannover ( Site 1207)</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+495116555280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynaekologisches Zentrum-Schwerpunkt Gyn. Onkologie ( Site 1205)</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4922890927671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum AoeR Duesseldorf ( Site 1210)</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492118117506</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte ( Site 1215)</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4920117433039</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus ( Site 1203)</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+493514586728</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz ( Site 1608)</name>
      <address>
        <city>Kecskemet</city>
        <state>Bacs-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3676516719</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 1607)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36302457110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1601)</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36209323256</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 1602)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612248600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 1600)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+365225585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1604)</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36304111268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Korhaz ( Site 1605)</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36304199969</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital ( Site 2202)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81527626111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital ( Site 2203)</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81798456111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital ( Site 2201)</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81245471111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital ( Site 2204)</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81822212291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital ( Site 2200)</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81669421331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital ( Site 2402)</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82532002624</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center ( Site 2408)</name>
      <address>
        <city>Incheon</city>
        <state>Incheon-gwangyeoksi [Incheon]</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821099335099</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 2406)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82319200441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital ( Site 2409)</name>
      <address>
        <city>Seongnam-si</city>
        <state>Kyonggi-do</state>
        <zip>13605</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+821030797022</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital ( Site 2407)</name>
      <address>
        <city>Suwon-si</city>
        <state>Kyonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82312194266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital ( Site 2403)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82220720850</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 2401)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82222288135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 2404)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82230103216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 2405)</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82234101254</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regionalny Szpital Specjalistyczny Latawiec ( Site 1917)</name>
      <address>
        <city>Swidnica</city>
        <state>Dolnoslaskie</state>
        <zip>58-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48748517220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow ( Site 1919)</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48122954139</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1908)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48225462522</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1913)</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48 501220811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1912)</name>
      <address>
        <city>Gliwice</city>
        <state>Slaskie</state>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48322788613</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o. ( Site 1909)</name>
      <address>
        <city>Pleszew</city>
        <state>Wielkopolskie</state>
        <zip>63-300</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48784648510</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Oncologico Baselga.Hospital Quiron. ( Site 0707)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34629839840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d Hebron ( Site 0701)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932746000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona ( Site 0702)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349322754003456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Arnau de Vilanova de Valencia ( Site 0706)</name>
      <address>
        <city>Valencia</city>
        <state>Valenciana, Comunitat</state>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34961976177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia ( Site 0705)</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34957012408</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria Navarra - Madrid ( Site 0700)</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+349135319207513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital ( Site 2304)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88677317123ext3267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 2303)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886623535354273</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital ( Site 2301)</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886225433535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center ( Site 2300)</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886228970011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital ( Site 2302)</name>
      <address>
        <city>Taipei</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886422052121ext1639</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 1502)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380676318171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CI Krivorizhskiy oncology dispensery ( Site 1504)</name>
      <address>
        <city>Kryviy Rih</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675393937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MI Precarpathian Clinical Oncology Center ( Site 1506)</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <state>Ivano-Frankivska Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380502094000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal non profit enterprise Regional Clinical Oncology Center ( Site 1512)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380506556166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI-Zaytsev institute of general and urgent surgery-NAMS ( Site 1518)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509799884</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Center Verum ( Site 1501)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380997799214</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Centre Consilium Medical ( Site 1514)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380503816916</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical center of the Limited Liability Company Yulis ( Site 1517)</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Zaporizka Oblast</state>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380667145005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Centre LLC Oncolife ( Site 1510)</name>
      <address>
        <city>Zaporizhzhya</city>
        <state>Zaporizka Oblast</state>
        <zip>69104</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380973153178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhytomyr Regional Oncology Center ( Site 1515)</name>
      <address>
        <city>Zhytomyr</city>
        <state>Zhytomyrska Oblast</state>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380675885098</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital ( Site 0915)</name>
      <address>
        <city>Inverness</city>
        <state>Highland</state>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441463706373</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust ( Site 0914)</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441619187372</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death Receptor 1 (PD-1, PD1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 1 (PD-L1, PDL1)</keyword>
  <keyword>Programmed Cell Death Receptor Ligand 2 (PD-L2, PDL2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

